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LETTERS TO THE EDITOR
Regarding “Stent grafts vs femoropopliteal bypass”
The randomized controlled trial (RCT) by Kedora et al1
showed that management of femoropopliteal (FP) arterial occlu-
sive disease using percutaneous treatment with an expanded poly-
tetrafluoroethylene (PTFE)/nitinol self-expanding stent graft was
comparable to surgical revascularization with conventional above
knee (AK)-FP bypass using synthetic material up to 12 months. In
the surgical bypass group, Dacron grafts were used in 64%, and
expanded PTFE was used in 36%. We would like to suggest,
however, that saphenous vein (SV) grafts should be used instead of
synthetic material as conduit of the FP bypass in the control group
because of the following reasons. According to themeta-analysis of
uncontrolled series by Pereira et al,2 SV grafts performed better
than PTFE grafts in AK-FP bypass. When only RCTs in the
systematic review of AK-FP bypass by Klinkert et al3 were consid-
ered, the patency of SV grafts was better than for PTFE grafts. The
most recent meta-analysis by us4 of currently available five RCTs
also demonstrated that SV grafts were superior to PTFE grafts in
AK-FP bypass: the pooled primary graft patency of SV and PTFE
grafts were 86.6% and 83.7% (P  .3957) at 1 year, 82.6% and
74.6% (P  .0198) at 2 years, 79.2% and 65.3% (P  .0011) at 3
years, 77.6% and 61.3% (P  .0001) at 4 years, and 76.4% and
56.1% (P  .0001) at 5 years, respectively. Because the type of
prosthetic (Dacron or PTFE) used for AK-FP bypass, grafts did not
affect 5-year patency rates in the RCT by Green et al,5 SV grafts
probably surpass both Dacron and PTFE grafts in patency of
AK-FP bypass. Therefore, to compare the efficacy of the stent graft
vs open surgical AK-FP bypass, conduit of the bypass would be SV
rather than Dacron or PTFE. If a stent graft is not superior to, but
comparable to AK-FP bypass using synthetic material, it might be
inferior to the bypass using SV grafts.
Hisato Takagi, MD, PhD
Toshiyuki Tanabashi, MD
Norikazu Kawai, MD
Takuya Umemoto, MD, PhD
Department of Cardiovascular Surgery
Shizuoka Medical Center
Shizuoka, Japan
REFERENCES
1. Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D.
Randomized comparison of percutaneous Viabahn stent grafts vs pros-
thetic femoral-popliteal bypass in the treatment of superficial femoral
arterial occlusive disease. J Vasc Surg 2007;45:10-6.
2. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA.
Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial
insufficiency. J Vasc Surg 2006;44:510-7.
3. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus
PTFE for above-knee femoropopliteal bypass. A review of the literature.
Eur J Vasc Endovasc Surg 2004;27:357-62.
4. Takagi H, Kato T, Kawai N, Umemoto T. Meta-analysis of randomized
controlled trials of saphenous vein versus polytetrafluoroethylene graft in
above-knee femoropopliteal bypass. J Vasc Surg (in press).
5. Green RM, Abbott WM, Matsumoto T, Wheeler JR, Miller N, Veith FJ,
et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year
results of a randomized trial. J Vasc Surg 2000;31:417-25.
doi:10.1016/j.jvs.2007.03.058
Reply
The response by Dr Takagi and his associates to our recent
publication “Randomized comparison of percutaneous Viabahn
stent grafts vs prosthetic femoral-popliteal bypass in the treatment
of superficial femoral arterial occlusive disease” is appreciated. The
comments bring to the forefront important comparisons of the
treatment of superficial femoral arterial occlusive disease with
prosthetic conduit versus vein conduit. The analysis and articles
that are cited certainly offer good argument for vein conduit as the
“gold standard” in vascular revascularization of superficial femoral
artery (SFA) occlusion and limb ischemia. In fact, in our recent
article, we acknowledge that our group also considers vein conduit
as the “gold standard” for this type of reconstruction.
Our current study, however, was not designed to compare
venous reconstruction of the SFA with a percutaneous nitinol
self-expanding stent graft covered with polytetrafluoroethylene
(PTFE). It was designed to compare this type of stent graft with
nonautologous conduit. This type of reconstruction would be of
particular benefit for the patient population that cannot undergo
revascularization with venous conduit. There are numerous pa-
tients who present with no venous conduit useable for bypass or
who may not be suitable surgical candidates. We conducted our
study to evaluate this percutaneous method of treatment of the
SFA to offer another treatment option besides surgical bypass
using prosthetic conduit.
As is demonstrated in our study, percutaneous treatment of
the SFA with a covered nitinol self-expanding stent graft is shown
to be equal to surgical bypass of the SFA with nonautologous
conduit up to 12 months. In addition, there is a faster return to
daily activities and a decreased hospital stay. We believe these
results to show promise, although longer follow-up is needed and
is currently in process at our institution. Any treatment method
must be individualized for each patient and, if possible, we agree
that the use of venous conduit for vascular reconstruction of the
SFA is ideal.
John Kedora, MD
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Regarding “Angio-Seal arterial puncture closing
device removal: some technical details”
In the article by Dregelid et al,1 the authors present a series of
four female patients affected by severe lower extremity ischemia
after use of Angio-Seal device, focusing on the importance of an
early detection of possible complications, such as thrombosis and
lower limb ischemia. However, from this article and from extensive
research in the English literature, in our opinion, there is no
consensus regarding the correct approach to remove the device in
case of complications.
In the light of our experience, a longitudinal arteriotomy
could not be always the method of choice to better approach the
arterial lesion, but should be reserved for selective cases when a
diffuse atherosclerotic involvement is present, or an extensive
injury of the intimal layer is supposed, such as in the case one of this
article.2 In fact, the arterial occlusion is often due to the thrombo-
sis around the Angio-Seal polymer bar in a stenotic tract of artery,
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while the intimal lesions, frequently limited on the posterior wall,
play a minor role.
In our opinion, a transverse arteriotomy at the level of the
Angio-Seal introduction site could lead to a safe removal of the
anchorage system, permitting a sufficient exploration of the poste-
rior intimal layer.We retain that this has been the surgical approach
on patient 3 in this report. Moreover, in the case of a posterior
intimal defect, a limited resection of the flap and a Kunlin suture
can be performed easily. This approach is preferable, in our opin-
ion, allowing the avoidance of a longitudinal arteriotomy and
usage of a prosthetic patch for the arterial reconstruction. In our
experience, the longitudinal arteriotomy can be reserved only
where there is an extensive intimal lesion, previously demonstrated
by a transverse arteriotomy or in cases of diffuse atherosclerotic
involvement of the common femoral artery.
Moreover, if longitudinal arteriotomy is the only option, we
suggest the use of an autologous saphenous vein patch to decrease
the possibility of infection as demonstrated by Gonzo et al.3-5
In conclusion, we believe the ischemic complication of the
Angio-Seal device should be approached by a transverse arteriot-
omy, without the use of prosthetic material. An eventual autolo-
gous vein patch is the preferred material when an arterial recon-
struction is needed.
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Reply
There is no scientific evidence to prefer either the transverse or
longitudinal arteriotomy for removal of endoluminally displaced
Angio-Seal sponges. We elected to use longitudinal arteriotomies
in all four patients who were the subjects of our report because
longitudinal arteriotomy provides better intraluminal exposure. In
three of the patients, the arteriotomy was closed without patch
insertion. Intraluminal displacement of Angio-Seal sponges often
is due to plaque. A longitudinal arteriotomy provides better expo-
sure and allows a more controlled removal of a plaque that pro-
trudes or that is partially avulsed due to interference with the
Angio-Seal device.
Although closure of longitudinal arteriotomy may produce
stenosis, which may be prevented by closure with a patch, it has
been shown experimentally that it is possible to close longitudinal
arteriotomies without creating significant stenosis even in thin rat
femoral arteries.1 In our experience, longitudinal arteriotomies
usually can be closed without creating a stenosis and without the
necessity of using a patch provided small bites are taken with the
suture and provided the suture is not tightened unnecessarily.
Whenever possible, it is desirable to avoid using prosthetic
material when an arteriotomy is being closed, and particularly in
the groin, because of the risk of infection and the prosthetic
material’s tendency to provoke foreign body reaction and throm-
bus formation. In the groin, a minor stenosis due to direct closure
without a patch may be preferable to patch closure due to the risk
of infection. When a patch has to be used, a vein patch is preferable
to a prosthetic patch,2-4 and it should not be so wide as to cause a
marked increase in luminal diameter at the arteriotomy site since a
localized arterial widening can cause turbulence and mural throm-
bus formation.5
Einar Dregelid, MD
Vascular Section, Department of Surgery
Haukeland University Hospital
Bergen, Norway
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Regarding “Perioperative Use of Statins Does not
Reduce Cardiovascular Risk”
In the article by Schouten et al,1 the authors included the
review of several recent studies that addressed the beneficial effect
of statin use in patients undergoing “major vascular, noncardiac
surgery.”
Soon after the publication of the article by Schouten et al
(August 2006),1 a systematic review by Kapoor et al2 to determine
the strength of evidence for using statins during the perioperative
period to reduce the risk of cardiovascular events was pub-
lished (November 2006). Owing to methodological heterogeneity
among studies, they carried out a meta-analysis of methodologi-
cally similar studies (eg, all randomized trials or all cohort studies).
Regarding perioperative death or acute coronary syndrome, pool-
ing the data from all 13 cohort studies gave a summary odds ratio
(OR) of 0.70 (95% confidence interval [CI], 0.57 to 0.87) with
statin use (1, favors statin use; 1, favors control). Certainly,
these 13 studies were methodologically similar because of all
cohorts. Obvious between-study heterogeneity concerning types
of surgery, however, was present in the pooled estimate derived
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